Alimera Sciences (NASDAQ:ALIM) Downgraded to “Neutral” at HC Wainwright

Alimera Sciences (NASDAQ:ALIM) was downgraded by investment analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday, MarketBeat reports. They currently have a $6.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 8.70% from the stock’s previous close. HC Wainwright also issued estimates for Alimera Sciences’ Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.14 EPS.

Several other equities analysts have also recently commented on the company. StockNews.com cut Alimera Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. Maxim Group began coverage on Alimera Sciences in a report on Monday, March 25th. They set a “buy” rating and a $10.00 price objective for the company.

Alimera Sciences Price Performance

ALIM stock opened at $5.52 on Tuesday. The stock has a 50-day simple moving average of $3.40 and a two-hundred day simple moving average of $3.66. Alimera Sciences has a twelve month low of $2.60 and a twelve month high of $5.65. The firm has a market capitalization of $289.19 million, a PE ratio of -3.52 and a beta of 1.14. The company has a quick ratio of 2.51, a current ratio of 2.62 and a debt-to-equity ratio of 1.71.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08). Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. The firm had revenue of $23.01 million for the quarter, compared to analysts’ expectations of $23.72 million. During the same period in the prior year, the firm posted ($0.71) EPS. On average, equities analysts predict that Alimera Sciences will post -0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Alimera Sciences

Institutional investors have recently modified their holdings of the company. Ancora Advisors LLC purchased a new stake in Alimera Sciences in the first quarter worth approximately $915,000. Hillsdale Investment Management Inc. bought a new stake in shares of Alimera Sciences in the 1st quarter worth approximately $169,000. Vanguard Group Inc. boosted its stake in shares of Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after purchasing an additional 396,506 shares in the last quarter. Fifth Lane Capital LP bought a new position in shares of Alimera Sciences during the 1st quarter valued at $83,000. Finally, Stonepine Capital Management LLC raised its position in Alimera Sciences by 0.4% in the 4th quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock worth $17,278,000 after purchasing an additional 15,773 shares during the period. 99.83% of the stock is currently owned by institutional investors.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).